Medical device with coating that promotes endothelial cell adherence and differentiation

• US 20070196422A1
• Filed: 10/27/2006
• Published: 08/23/2007
• Est. Priority Date: 03/15/2000
• Status: Abandoned Application

• Current Assignee: OrbusNeich Medical Pte Ltd
• Original Assignee: Orbusneich Medical Incorporated (Orbusneich Medical)
• Inventors: Rowland, Stephen, Cottone, Robert, Kutryk, Michael, Kuliszewski, Michael
• Application Number:
  US11/588,480
• Publication Number:
  US 20070196422A1
• Time in Patent Office: Days
• US Class Current: 424/423
• CPC Class Codes: A61K 31/721 Dextrans
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: C08L 5/02 Dextran; Derivatives thereof

Abstract

Compositions and methods are provided for producing a medical device such as a stent, a stent graft, a synthetic vascular graft, heart valves, coated with a biocompatible matrix which incorporates antibodies, antibody fragments, or small molecules, which recognize, bind to and/or interact with a progenitor cell surface antigen to immobilize the cells at the surface of the device. The coating on the device can also contain a compound or growth factor for promoting the progenitor endothelial cell to accelerate adherence, growth and differentiation of the bound cells into mature and functional endothelial cells on the surface of the device to prevent intimal hyperplasia. Methods for preparing such medical devices, compositions, and methods for treating a mammal with vascular disease such as restenosis, artherosclerosis or other types of vessel obstructions are disclosed.

Claims

1-71. -71. (canceled)

72. A bioactive implantable stent comprising a stent structure with a surface coating of a biodegradable, bioactive polymer, wherein the polymer comprises at least one bioligand covalently bound to the polymer wherein the bioligand binds specifically to integrin receptors on progenitors of endothelial cells (PECs) in circulating blood.

73. The stent of claim 72, wherein the stent structure is porous and the coating is multilayered and encapsulates the stent structure, the multilayered coating comprising:

an outer drug-eluting biodegradable polymer layer, which sequesters an unbound bioactive agent that promotes endogenous healing of epithelium; and

an inner layer of the biodegradable, biocompatible polymer with the at least one bioligand covalently bound to the biocompatible biodegradable polymer.

74. The stent of claim 73;

further comprising a biodegradable barrier layer lying between and in contact with the outer layer and the inner layer and which barrier layer is impermeable to the drug.

75. The stent of claim 72, wherein the bioligand comprises an antibody that specifically binds to an integrin receptor on the PECs.

76. The stent of claim 75, wherein the antibody is a monoclonal antibody.

77. The stent of claim 75, wherein the bioligand comprises a first member of a specific binding pair and the target is an antibody tagged with a second member of the specific binding pair, wherein the antibody specifically binds to the integrin receptor on the PECs.

78. The stent of claim 72, wherein the stent is sized for implanting in the vasculature.

79. The stent of claim 72, wherein the biodegradable, biocompatible polymer further comprises at least one bioactive agent selected to promote production of nitric oxide by endothelial cells at a locus adjacent to the stent.

80. The stent of claim 79, wherein the bioactive agent donates, transfers or releases nitric oxide, elevates endogenous levels of nitric oxide, stimulates endogenous synthesis of nitric oxide, or serves as a substrate for nitric oxide synthase.

81. The stent of claim 72, wherein the stent is sized for implanting in the vasculature.

82. The stent of claim 72, wherein the biodegradable, biocompatible polymer further comprises at least one bioactive agent selected to promote production of nitric oxide by endothelial cells at a locus adjacent to the stent.

83. The stent of claim 81, wherein the bioactive agent donates, transfers or releases nitric oxide, elevates endogenous levels of nitric oxide, stimulates endogenous synthesis of nitric oxide, or serves as a substrate for nitric oxide synthase.

84. The stent of claim 72, wherein the at least one bioligand is conjugated to the biodegradable, biocompatible polymer on the exterior of the polymer coating.

85. The stent of claim 72, further comprising at least one additional bioactive agent suitable for promoting healing in a damaged artery.

86. The stent of claim 72, wherein there is a total of about 5 to about 150 molecules of the bioactive agent and additional bioactive agent per biodegradable, biocompatible polymer molecule chain.

94. A method for treating damaged arterial endothelium in heart or limb in a patient having Type II diabetes comprising implanting a stent according to claim 72 to promote natural healing of damaged endothelium in the artery wall of the patient.

95. The method of claim 94, wherein damage endothelium is in the heart of the patient.

96. The method of claim 94, wherein the damaged arterial endothelium is peripheral limb tissue.

87. A kit comprising a bioactive implantable stent comprising a stent structure with a surface coating of a biodegradable, bioactive polymer and at least one bioligand or first member of a specific binding pair is covalently bound to the biodegradable, biocompatible polymer, wherein the bioligand or the first member binds specifically to a target on therapeutic PECs.

88. The kit of claim 87, wherein the stent structure is porous and the coating is multilayered and encapsulates the stent structure, the multilayered coating comprising:

an outer drug-eluting biodegradable polymer layer, which sequesters an unbound bioactive agent for promoting endogenous endothelial healing; and

an inner layer of the biodegradable, biocompatible polymer with the at least one bioligand or the first member covalently bound thereto, wherein the bioligand binds specifically to integrin receptors in PECs.

89. The kit of claim 88, wherein the multilayered tubular coating further comprises a biodegradable barrier layer lying between and in contact with the outer layer and the inner layer and which barrier layer is impermeable to the drug.

90. The kit of claim 88, wherein the bioligand comprises an antibody.

91. The kit of claim 88, wherein the bioligand comprises an antibody tagged with a first member of a specific binding pair and the kit further comprises:

b) a monoclonal antibody that binds specifically to an integrin receptor on PECs; and

c) a second member of the specific binding pair bound to the monoclonal antibody.

92. The kit of claim 91, wherein the bioligand is a first member of a specific binding pair and the kit further comprises:

b) a second monoclonal antibody that binds specifically to integrin receptors on PECs; and

c) a second member of the specific binding pair bound to the second monoclonal antibody.

93. A tubular sheath comprising a biodegradable, bioactive polymer, wherein the polymer comprises at least one bioligand covalently bound to the polymer, wherein the bioligand specifically binds to an integrin receptors on PECs.

97. A method comprising using a polymer as a medical device, a pharmaceutical, or as a carrier for covalent immobilization of a bioligand or first member of a specific binding pair that specifically attaches to an integrin receptor in PECs in the circulating blood of a patient with Type II diabetes into which the polymer is implanted, wherein:

a) the bioligand forms a specific binding pair with the integrin receptor on PECs in circulating blood;

b) the bioligand forms a specific binding pair with an antibody that binds specifically to the integrin receptor;

or c) the antibody is tagged with a first member of a specific binding pair and the bioligand comprises a second member of the specific binding pair.

98. The method of claim 97, wherein the bioligand is an antibody that binds specifically to the integrin receptor on the PECs.

99. An implantable medical device having a biodegradable, bioactive polymer coated upon at least a portion of a surface thereof, wherein the polymer comprises at least one bioligand covalently bound to the polymer, wherein the bioligand specifically binds an integrin receptor on PECs found in peripheral blood.